

N-methyl-D-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: A revolving neurochemical axis for therapeutic intervention?

John J. Haddad^{a,b,*}

^a *Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut, Lebanon*

^b *Departments of Biology and Biomedical Sciences, Faculty of Arts and Sciences, Lebanese International University, Beirut, Lebanon*

Received 10 November 2003; received in revised form 10 December 2004; accepted 27 October 2005

Abstract

Excitatory synaptic transmission in the central nervous system (CNS) is mediated by the release of glutamate from presynaptic terminals onto postsynaptic channels gated by *N*-methyl-D-aspartate (NMDA) and non-NMDA (AMPA and KA) receptors. Extracellular signals control diverse neuronal functions and are responsible for mediating activity-dependent changes in synaptic strength and neuronal survival. Influx of extracellular calcium ($[Ca^{2+}]_e$) through the NMDA receptor (NMDAR) is required for neuronal activity to change the strength of many synapses. At the molecular level, the NMDAR interacts with signaling modules, which, like the mitogen-activated protein kinase (MAPK) superfamily, transduce excitatory signals across neurons. Recent burgeoning evidence points to the fact that MAPKs play a crucial role in regulating the neurochemistry of NMDARs, their physiologic and biochemical/biophysical properties, and their potential role in pathophysiology. It is the purpose of this review to discuss: (i) the MAPKs and their role in a plethora of cellular functions; (ii) the role of MAPKs in regulating the biochemistry and physiology of NMDA receptors; (iii) the kinetics of MAPK–NMDA interactions and their biologic and neurochemical properties; (iv) how cellular signaling

Abbreviations: AA, arachidonic acid; AIDS, acquired immunodeficiency syndrome; ALS, amyotrophic lateral sclerosis; AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; APV, 2-amino-5-phosphonovaleate; 2-AP5, 2-amino-5-phosphonopentanoic acid; ATF, activating transcription factor; BAPTA-AM, 1,2-bis(*o*-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid; BDNF, brain-derived neurotrophic factor; BSO, L-buthionine-(*S,R*)-sulfoximine; CaM, Ca^{2+} /calmodulin; CaMK, Ca^{2+} /calmodulin-dependent protein kinase; CAT, catalase; CEE, conjugated equine estrogens; CNS, central nervous system; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; CPP, 3-[(*RS*)-2-carboxypiperazin-4-yl]-propyl-1-phosphonate; CREB, cAMP responsive element binding protein; CS, conditioned stimulus; DA, dopamine; ECS, electroconvulsive shock; EGF, epidermal growth factor; ERK, extracellular receptor kinase; ERT, estrogen replacement therapy; ERT-kinase, EGF receptor threonine kinase; FGF, fibroblast growth factor; GAP, GTPase activating protein; γ -GCS, γ -glutamylcysteine synthetase; GDNF, glial cell line-derived neurotrophic factor; GEF, guanine nuclear exchange factor; GluR, glutamate receptor; GSH, glutathione; GSTp, glutathione *S*-transferase P; HEK, human embryonic kidney; HFS, high-frequency stimulation; H_2O_2 , hydrogen peroxide; IEG, immediate early gene; IGF, insulin-like growth factor; IL, interleukin; iNOS, inducible nitric oxide synthase; IRS, insulin receptor-substrate; JIP, JNK-interacting protein; JNK, Jun N-terminal kinase; KA, kainic acid; LPS, lipopolysaccharide-endotoxin; LTD, long-term depression; LTM, long-term memory; LTP, long-term potentiation; MAP, microtubule associated protein; MAPK, mitogen-activated protein kinase; MAPKK, MAP kinase kinase; MAPKKK, MAP kinase kinase kinase; MBP-kinase, myelin basic protein kinase; MCPG, α -methyl-4-carboxy-phenyl glycine; METH, methamphetamine; MF, mossy fiber; mGluR, metabotropic glutamate receptor; MI, metabolic inhibition; MKP, MAPK phosphatase; MLK, mixed lineage kinase; MSG, monosodium glutamate; NGF, nerve growth factor; NO, nitric oxide; NMDA, *N*-methyl-D-aspartate; NMDAR, NMDA receptor; NMDA-EPSP, NMDA excitatory postsynaptic potential; NRC, NMDA receptor multi-protein complex; PAK, p21-activated kinase; PCP, phenylcyclidine; PDGF, platelet-derived growth factor; PI 3-kinase, phosphatidylinositol 3-kinase; PLA2, phospholipase A2; PKA, protein kinase A; PKC, protein kinase C; PPD, paired-pulse depression; PTK, protein tyrosine kinase; PTX, pertussis toxin; RGC, retinal ganglion cell; RNS, reactive nitrogen species; RSK-kinase, ribosomal S6 protein kinase; RTK, receptor tyrosine kinase; SAPK, stress-activated protein kinase; SD, succinate dehydrogenase; *S*-DHPG, (*S*)-dihydrophenylglycine; SH, Src homology; SIN-1, 3-morpholinylsydnnonimine; SNAP, *S*-nitroso-*N*-acetylpenicillamine; SNOC, *S*-nitrosocysteine; SOD, superoxide dismutase; SRF, serum response factor; STM, short-term memory; TBS, theta-burst; TCF, ternary complex factor; TEA, tetraethyl-ammonium chloride; TGF, transforming growth factor; TNF, tumor necrosis factor; VSCC, voltage-sensitive Ca^{2+} channel; z-VAD-fmk, *N*-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone

* Present address: In affiliation with Prof. Bared Safieh-Garabedian, Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut Lebanon. Previous address: Severinghaus-Radiometer Research Laboratories, School of Medicine, University of California, San Francisco, California, USA. Tel.: +961 1 350000; fax: +961 1 374374.

E-mail address: johnjhaddad@yahoo.co.uk.

pathways, related cofactors and intracellular conditions affect NMDA–MAPK interactions and (v) the role of NMDA–MAPK pathways in pathophysiology and the evolution of disease conditions. Given the versatility of the NMDA–MAPK interactions, the NMDA–MAPK axis will likely form a neurochemical target for therapeutic interventions.

© 2005 Published by Elsevier Ltd.

Keywords: Biochemistry; Calcium; CNS; Glutamate; Kinase; MAPK; Neurochemistry; NMDA; Pathophysiology; Phosphorylation; Signaling

Contents

1. Introduction and general background	254
1.1. Glutamate receptors (GluRs) in the CNS—physiology and pathophysiology	254
1.2. GluRs in the CNS—the NMDA receptor subtype	254
1.3. GluRs and NMDARs—pathway interactions	254
1.4. The purpose of undertaking this survey	254
2. MAPK signaling pathways: an overview	255
2.1. MAPK identification and nomenclature	255
2.2. MAPK biochemistry and properties	255
2.3. MAPK signaling pathways and activation	255
3. NMDARs: analytical structure, biophysical properties and biochemical interactions	257
3.1. Receptor bio-analytical assessment—biophysics	257
3.2. NMDAR biophysical and biochemical properties	257
3.3. NMDAR regulation during development, stress and exogenous pharmacological interventions	259
3.3.1. Development and distribution	259
3.3.2. The role of stress	260
3.3.3. The role of nitration	260
3.3.4. NMDA regulation and pathophysiology	260
3.3.5. Pharmacological modulation of the NMDAR	260
3.3.6. Ethanol and the modulation of the NMDAR	261
4. NMDA-mediated regulation of MAPK signaling pathways	261
4.1. NMDA-mediated regulation of G-coupled receptor proteins	261
4.1.1. NMDA, CaMK and MAPK regulation	261
4.1.2. NMDA, AMPA and MAPK regulation	262
4.1.3. NMDA, CREB and MAPK regulation	262
4.1.4. NMDA, KA and MAPK regulation	262
4.2. NMDA, MAPKs and apoptosis-related pathways	263
4.2.1. Insulin-like growth factors and NMDA-mediated excitotoxicity	263
4.2.2. Egr-1 and NMDA-mediated excitotoxicity	263
4.2.3. MAPKs and NMDA-mediated neurotoxicity	264
4.2.4. Neutrophins, MAPKs and NMDA-mediated neurotoxicity	264
4.2.5. Caspases, MAPKs and NMDA-mediated neurotoxicity	264
4.2.6. IEG (pip), MAPKs and NMDA-mediated neurotoxicity	265
4.2.7. PKC, MAPKs and NMDA-mediated neurotoxicity	265
4.3. NMDA, MAPKs and long-term potentiation	265
4.3.1. General aspects of NMDA–MAPK interactions in the regulation of LTP	265
4.3.2. Genetic control of NMDA–MAPK interactions in the regulation of LTP	266
4.4. NMDA, MAPKs and long-term depression	267
4.5. NMDA, MAPKs and short- and long-term memory	268
4.6. NMDA, MAPKs and electroconvulsive shock	269
4.7. NMDA, MAPKs and oxidative stress: role of oxidants and inflammatory mediators	269
4.7.1. Role for hydrogen peroxide (H_2O_2)	269
4.7.2. Role for superoxide anion ($O_2^{\bullet -}$)	269
4.7.3. Role for nitric oxide (NO)	270
4.7.4. Role for ammonia	270
4.7.5. Role for cytokines and inflammatory-related mediators	270
4.8. NMDA, MAPKs and the role of regulatory transcription factors and cofactors	271
4.9. NMDA, MAPKs and developmental processes	271
4.10. NMDA, MAPKs and pain/hyperalgesia mechanisms	272
4.11. NMDA, MAPKs and behavioral mechanisms	272
4.12. NMDA, MAPKs and obesity	273
4.13. NMDA, MAPKs and pathophysiology: potential interactions in the evolution of disease/injury	274

Download English Version:

<https://daneshyari.com/en/article/9435137>

Download Persian Version:

<https://daneshyari.com/article/9435137>

[Daneshyari.com](https://daneshyari.com)